Anupam Rasayan India LimitedChemicalsANURAS
Q1 FY27 concall · earnings callAnupam Rasayan India Limited
Anupam Rasayan began FY27 with strong 36% revenue growth, driven by new product commercialization and the strategic integration of acquisitions to build a diversified specialty chemicals platform.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Consolidated Total Income | ₹668 Cr | 36% | |
| Revenue from Operations | ₹655 Cr | — | |
| Consolidated EBITDA | ₹175 Cr | 35% | |
| EBITDA Margin | 26% | — | |
| Consolidated PAT | ₹51 Cr | 6% | |
| PAT Margin | 8% | — |
Financials
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹390.14 Cr+32% YoY+32.7% QoQ | ₹54.21 Cr+108.3% YoY+77% QoQ | ₹2.57+51.2% YoY+70.2% QoQ |
| Q2 FY25 | ₹293.96 Cr-25% YoY+15.6% QoQ | ₹30.62 Cr-37.1% YoY+150.8% QoQ | ₹1.51-60.1% YoY+319.4% QoQ |
| Q1 FY25 | ₹254.20 Cr-34.2% YoY-36.6% QoQ | ₹12.21 Cr-76.6% YoY-69.8% QoQ | ₹0.36-92.6% YoY-87.2% QoQ |
| Q4 FY24 | ₹401.01 Cr-16.4% YoY+35.7% QoQ | ₹40.47 Cr-44.3% YoY+55.5% QoQ | ₹2.81-59.9% YoY+65.3% QoQ |
| Q3 FY24 | ₹295.52 Cr-22.8% YoY-24.6% QoQ | ₹26.02 Cr-52.2% YoY-46.6% QoQ | ₹1.70-68% YoY-55% QoQ |
TL;DR
- Consolidated total income grew 36% year-on-year to INR668 crores.
- Successfully commercialized Ethyl Trifluoroacetate (ETFA) using flow chemistry, claimed as a global first.
- Signed a Letter of Intent with BASQUEVOLT for a potential USD300 million opportunity over 10 years.
- The Jayhawk acquisition contributed 20-22% of quarterly revenue.
- The proposed acquisition of Bliss GVS Pharma is expected to conclude in the first half of September.
- Major capex cycle is complete; future capex is estimated at INR70-80 crores.
Said on the call
“We are proud to be the first company globally to commercialize ETFA through this technology.”
From the Q&A
| Topic | What management said |
|---|---|
| Bliss GVS Acquisition Timeline | Transaction expected to be fully concluded by first half of September; SEBI approval and open offer are complete. |
| Jayhawk Financials | Contributed 20-22% of revenue (~INR145 crores) with EBITDA margins of 19-20%; PAT was ~INR9 crores. |
| Polymer Business Sustainability | Polymer business should be 20-25% on standalone basis and 30-35% on consolidated basis. |
| Future EBITDA Margin Guidance | Guidance is for 24-26% standalone EBITDA margin and 22-24% consolidated. |
| ETFA Commercialization Significance | Claimed as the only company globally to commercialize ETFA via flow chemistry; targets a USD0.5 billion market with better cost parameters and margin profile. |
| Capex Outlook | Major capex cycle completed; future capex estimated at INR70-80 crores, primarily for maintenance/repurposing. |
| Agri Business Outlook | Demand recovery is there; business is stable but contribution will drop as other segments grow faster. |
| Funding for Bliss Acquisition | Will involve ~INR300 crores of debt in a subsidiary, with the balance via an equity-linked instrument. |
Guidance
- Polymer business to be 20-25% on standalone basis and 30-35% on consolidated basis.
- Standalone EBITDA margin guidance: 24-26%.
- Consolidated EBITDA margin guidance: 22-24%.
- Organic revenue growth expected to be 25% plus/minus a couple of percentage points.
- Jayhawk to add 10-15% to revenue growth.
- Cumulative signed LOIs and contracts represent roughly INR18,000 crores of potential business over their respective tenures.
- Working capital expected to improve in coming quarters.
Source
Summary written from the transcript filed by Anupam Rasayan India Limited for the call held on 14 Aug 2026; published 20 Aug 2026, 17:55 IST.
More Q1 FY27 concalls ·How verification works ·Report an error